Ironwood Pharmaceuticals Community
Our community narratives are driven by numbers and valuation.
Value any stock for free in seconds
Get alerts and valuation updates
Participate in discussions
WA
Based on Analyst Price Targets
Emerging Prospects In Pharma Innovation Fuel Future Growth Potential
Key Takeaways Strong LINZESS demand and apraglutide's market potential could drive future revenue, contingent on stable pricing and regulatory success. Reduced R&D spending and strategic focus on high-potential assets may enhance financial stability and boost future earnings.
View narrativeUS$12.50
FV
70.6% undervalued intrinsic discount9.99%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
2 days ago author updated this narrative